Barinthus Biotherapeutics (BRNS) Stock Price, News & Analysis

Company Overview

Barinthus Biotherapeutics plc is a clinical-stage biotechnology company developing T-cell immunotherapies designed to treat autoimmune diseases, chronic infections and cancer. The company’s approach is intended to direct or regulate immune responses with greater specificity, with the goal of restoring immune tolerance or strengthening disease-fighting T-cell activity.

Barinthus’ product pipeline includes VTP-1000, an investigational antigen-specific therapy being developed for celiac disease, and VTP-300, a therapeutic vaccine candidate aimed at chronic hepatitis B infection. The company has also developed programs targeting human papillomavirus-related diseases and cancers. Its candidates are based on proprietary vaccine and immunotherapy technologies designed to stimulate targeted T-cell responses.

The company was originally established as Vaccitech, a biotechnology spinout associated with the University of Oxford, before changing its name to Barinthus Biotherapeutics. It is headquartered in the United Kingdom and conducts research and clinical development activities internationally, including in the United States. Barinthus is led by Chief Executive Officer William Enright.

Key Stats

• Today's Range: $0.74 to $0.74
• 50-Day Range: $0.72 to $0.78
• 52-Week Range: $0.51 to $1.83
• Volume: N/A
• Average Volume: 83,130 shs
• Market Capitalization: $30.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Barinthus Biotherapeutics Stock Analysis - MarketRank™

Barinthus Biotherapeutics scored higher than 32% of companies evaluated by MarketBeat, and ranked 764th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Barinthus Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Barinthus Biotherapeutics has a consensus price target of $4.00, representing about 440.5% upside from its current price of $0.74.

Amount of Analyst Coverage

Barinthus Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Barinthus Biotherapeutics are expected to decrease in the coming year, from ($0.93) to ($1.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Barinthus Biotherapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Barinthus Biotherapeutics is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Barinthus Biotherapeutics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for BRNS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Barinthus Biotherapeutics does not currently pay a dividend.

Dividend Growth

Barinthus Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added Barinthus Biotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Barinthus Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.50% of the stock of Barinthus Biotherapeutics is held by insiders.

Percentage Held by Institutions

25.20% of the stock of Barinthus Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BRNS
• Previous Symbol: NASDAQ:BRNS
• CIK: 1828185
• Web: www.barinthusbio.com
• Phone: 44-1865-818-808
• Fax: N/A
• Employees: 107
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Barinthus Biotherapeutics: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +440.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$66.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -59.15%
• Return on Assets: -43.80%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.54
• Quick Ratio: 5.54

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.82 per share
• Price / Book: 0.41

Miscellaneous

• Outstanding Shares: 40,849,000
• Free Float: 37,377,000
• Market Cap: $30.23 million
• Optionable: N/A
• Beta: -0.37